Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the population prevalence of critical body weight loss ( more than 5% from
baseline) in patients with Head and Neck cancer.
Secondary Objectives:
To evaluate the impact of appetite, and performance status; To evaluate the change of quality
of life (QoL); To evaluate the incidence of infection and hospitalization; To evaluate the
safety profiles